Diabetes 53:S92-S96, 2004
© 2004 by the American Diabetes Association, Inc.
Section II: Beta-Cell Therapeutic Targets Other Than ATP-Sensitive K+ Channels |
Beta-Cell-Targeted Expression of a Dominant-Negative Mutant of Hepatocyte Nuclear Factor-1 in Mice
Diabetes Model with ß-Cell Dysfunction Partially Rescued by Nonglucose Secretagogues
Maria Sörhede Winzell1,
Giovanni Pacini2,
Claes B. Wollheim3, and
Bo Ahrén1
1 Department of Medicine, Lund University, SE-221 84 Lund, Sweden
2 Metabolic Unit, Institute of Biomedical Engineering (ISIB), National Research Council (CNR), Padova, Italy
3 Experimental Diabetology Group, Department of Cell Physiology and Metabolism, University Medical Center, Geneva, Switzerland
We studied islet function in mice with ß-cell-targeted expression of a dominant-negative mutant of hepatocyte nuclear factor (HNF)-1 . At age 23 months, anesthetized transgenic and wild-type male mice underwent an intravenous glucose (1 g/kg) tolerance test (IVGTT). It was found that transgenic mice had an abolished insulin response in association with severe glucose intolerance. In other tests, the 5-min insulin response to intravenous arginine was impaired by 79% (P = 0.032) and the 15-min insulin response to gastric glucose was suppressed by 97% (P = 0.006). In islets incubated for 60 min, the insulin response to glucose (3.322.2 mmol/l) was impaired by >80% in transgenic mice. In contrast, insulin responses to nonglucose secretagogues were only partially suppressed (to GLP-1 [100 nmol/l] by 40%, to carbachol [1 µmol/l] by 20%, and to palmitate [0.5 mmol/l] by 15%), whereas the response to depolarization by KCl (50 mmol/l) was not reduced. Finally, the IVGTT data insulin sensitivity in transgenic mice was not significantly different from that of wild-type mice. Thus, mice with targeted suppression of ß-cell HNF-1 represent a good diabetes model exhibiting severely impaired insulin secretion after glucose with marked glucose intolerance. In contrast, the insulin responses to nonglucose stimuli are not suppressed when the islet insulin content is taken into account.
Address correspondence and reprint requests to Dr. Bo Ahrén, Department of Medicine, Lund University, B11 BMC, SE-221 84 Lund, Sweden. E-mail: bo.ahren{at}med.lu.se

CiteULike Del.icio.us Digg Reddit Technorati What's this?
Copyright © 2004 by the American Diabetes Association.
|
|
| |
|